← Eichor
Study identifier: NCT06882408 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

The Objective of This Study is to Evaluate the Perfomance of a Photorefraction Device for Screening Ametropia in Children. Eligible Participants Will Undergo Multiple Refractive Error Measurements, Visual Acuity and Strabismus Assessments During a Single Evaluation Visit.

Condition: Ametropia · Myopia; Refractive Error · Myopia; Astigmatism  ·  Sponsor: Essilor International

PhaseNA
Planned participants315
Who can joinAll sexes, 3 Years to 8 Years
Healthy volunteersYes

About this study

The goal of this clinical trial is to evaluate the performance of a photorefraction screener in terms of sensibility, sensitivity and accuracy on children aged 3 to 8 y.o. The main objectives of the study are: * Evaluate the performances of the device in comparison with the gold standard, i.e. a tabletop refractometer. * Assess the agreement of the measures obtained with the device with those obtained with the gold standard.

This description comes directly from the study's public registry record.

Talk to the study team

Sara Cadoni  ·  +33 642665760  ·  cadonis@essilor.fr

Always discuss trial participation with your own doctor first.

Locations (2)

Dr Krafft private practiceNancy, France, FranceNot Yet Recruiting
Hôpital civil de StrasbourgStrasbourg, France, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06882408